Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04678011

A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy

The purpose of this study is to determine the efficacy and safety of a personalised surveillance and intervention protocol for patients with familial adenomatous polyposis (FAP) that have undergone (procto)colectomy.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Familial adenomatous polyposis (FAP) is characterized by formation of up to hundreds to thousands of polyps throughout the entire colon and rectum. When left untreated, nearly all patients with FAP develop colorectal cancer at a median age of 35-45 years. To prevent colorectal cancer in patients with FAP, prophylactic colorectal surgery is performed. The preferred surgical procedures for FAP are a restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) or a subtotal colectomy with ileorectal anastomosis (IRA) or ileosigmoidal anastomosis (ISA).

After both types of prophylactic colorectal surgery, subtotal colectomy with IRA/ISA or proctocolectomy with IPAA, patients will require life-long surveillance because disease progression and development of new adenomas in retained rectum, pouch or residual rectal cuff will occur.

The 10-years risk of developing one or more adenomas in the rectum after IRA is 100% compared to 33% in the pouch after IPAA. The risk of developing rectal cancer after IRA was found to be 9% and 11% in two large studies with a median follow-up of 12.8 and 15 years, respectively. One study showed that the 10-years risk of developing a carcinoma in the pouch was 1%. As patients are usually operated at a young age, and nowadays have a long life-expectancy, the actual cumulative life-time risk will presumably be higher.

The recently published ESGE (European Society of Gastrointestinal Endoscopy) polyposis guideline recommends a one to two yearly endoscopic surveillance interval after prophylactic colorectal surgery in FAP, both for patients that underwent IRA/ISA and IPAA, with removal of all polyps >5mm. This recommendation is based on expert-opinion, since no studies have been reported comparing the efficacy and safety of different surveillance intervals. No advices are provided on which patients will benefit from which surveillance interval.

With the proposed study, the investigators aim to provide evidence for personalized endoscopic surveillance for patients with FAP that have undergone (procto)colectomy with construction of an IRA/ISA or IPAA with the goal to prevent development of advanced neoplasia (AN) by endoscopically removing lesions before they progress to AN.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of FAP, at least one of following: genetic diagnosis (proven APC germline mutation) and/or clinical diagnosis (>100 colorectal adenomas in combination with a positive family history of FAP)
  • Have undergone prophylactic (procto)colectomy with IRA/ISA or IPAA
  • Age 18 years or older

Exclusion criteria

  • Not able to remove all polyps with an indication for removal during (multiple) clearing endoscopies
  • Cancer at baseline endoscopy
  • Need for surgery

Treatment and study plan

Personalized surveillance and intervention protocol

Procedure

This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 6 months and 2 years, depending on severity of polyposis and performed endoscopic interventions.

Primary outcomes

  1. Advanced neoplasia

    Time frame: Up to 5 years

    Incidence of advanced neoplasia (advanced adenoma and cancer). An advanced adenoma is defined as size ≥ 10mm and/or high-grade dysplasia. This surveillance and intervention protocol will be considered successful when the incidence of advanced neoplasia is less than 5% after a study period of 5 years.

Secondary outcomes

  1. Characteristics polyps

    Time frame: Up to 5 years

    Incidence and characteristics of polyps detected/removed in patients with IRA/ISA and IPAA

  2. Radicality of different endoscopic intervention techniques

    Time frame: Up to 5 years

    Rate of radical endoscopic interventions

  3. Feasibility endoscopic interventions

    Time frame: Up to 5 years

    Incidence of lesions not amenable to endoscopic removal

  4. Surgical interventions

    Time frame: Up to 5 years

    Incidence of surgical interventions

  5. Surveillance burden

    Time frame: Up to 5 years

    Surveillance burden (number of endoscopies per patient)

  6. Complications

    Time frame: Up to 5 years

    Incidence of endoscopy related complications

Sponsors and collaborators

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Other

Collaborators

  • Hospital Clinic of Barcelona
  • Hospital General Universitario de Alicante
  • Hvidovre University Hospital
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna
  • Leiden University Medical Center
  • M.D. Anderson Cancer Center
  • Maria Sklodowska-Curie National Research Institute of Oncology
  • Radboud University Medical Center
  • St Mark's Hospital Foundation
  • The Netherlands Cancer Institute
  • University Hospital, Bonn

Registry information

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Dec 21, 2020
Registry last updated
Feb 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.